SciSparc (SPRC) Notes Payables (2018 - 2025)
SciSparc (SPRC) posted Notes Payables of $659000.0 for Q2 2025, down 84.45% sequentially from $4.2 million in Q4 2024, and down 73.08% YoY from $2.4 million in Q2 2024.
SciSparc (SPRC) Notes Payables (2018 - 2025) Analysis & Trends
SciSparc has reported Notes Payables for 4 years, with the latest figure at $659000.0 in Q2 2025.
- Quarterly Notes Payables fell 73.08% year-over-year to $659000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $659000.0 (down 73.08% YoY) and the FY2024 annual result came in at $4.2 million, changed N/A from the prior year.
- Notes Payables slipped to $659000.0 in Q2 2025 per SPRC's latest filing, from $4.2 million in the prior quarter.
- Over five years, Notes Payables peaked at $4.2 million in Q4 2024 and troughed at $659000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 659,000.00 |
| Dec 31, 2024 | 4.24 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Dec 31, 2020 | 188,000.00 |
| Jun 30, 2020 | 61,000.00 |
| Dec 31, 2018 | 874,000.00 |